• Aliases: MEDI-538; MT-103; AMG-103
    • A recombinant, single-chain, anti-CD19/anti-CD3 bispecific mAb that possesses two antigen-recognition sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the TCR, and one for CD19, a TAA overexpressed on the surface of B cells
    • FDA approved for relapsed or refractory B-cell acute lymphoblastic leukemia
    • Recommended dose: Each induction and consolidation treatment cycle consists of 4 weeks of continuous infusion followed by a 2-week treatment-free interval (allow at least 2 weeks treatment-free between cycles). Each continued therapy cycle consists of 4 interval. Therapy involves up to two induction cycles followed by three additional cycles for consolidation and up to four additional cycles of continued therapy (a total of up to nine cycles).
    Other topics in Targeted and Immunotherapy Agents